

## Periodontal Vaccines: A Dental Regime! Systematic Review

Rimi Najeeb<sup>1\*</sup>, Anamika Sharma<sup>2</sup> and Mehvish Saleem<sup>3</sup>

<sup>1</sup>Department of Periodontology and Implantology, Subharti Dental College and Hospital, Swami Vivekanand Subharti University, Meerut, UP, India

<sup>2</sup>Head of Department (HOD), Lala Lajpat Rai Memorial Medical College (LLRM), Meerut, UP, India

<sup>3</sup>Lecturer, Department of Periodontology, Subharti Dental College and Hospital, Swami Vivekanand Subharti University, Meerut, UP, India

\*Corresponding Author: Rimi Najeeb, Department of Periodontology and Implantology, Subharti Dental College and Hospital, Swami Vivekanand Subharti University, Meerut, UP, India.

Received: May 18, 2020; Published: May 30, 2020

### Abstract

**Background:** The infective etiology of periodontitis is perplexing and no corrective treatment methodology exists. Periodontal diseases are chronic bacterial infections that lead to gingival inflammation, periodontal tissue destruction and alveolar bone loss. Vaccination is a method that results in specific immune resistance to a bacteriological or viral infection, Periodontal sickness is multifactorial the multifaceted nature of the periodontopathic microscopic organisms can be an issue in assurance of Antigens. Chronic periodontitis is a long-lasting infection of the gum tissues, produced by an excess of dental plaque also the body's immune reaction to the harmful bacteria. It can cause the loss of bone and soft tissues and shows evidence of chronic periodontitis with a rise in the size of risk of certain cancers, rheumatoid arthritis and Alzheimer's Disease.

**Objective of the Study:** The main objective of periodontal vaccine is to identify the antigens convoluted in the damaging method of periodontitis counter to which antibodies could be aroused to exert protection.

**Aims of the Study:** To review the evidence that active or passive immunization against periodontitis provides immune protection also to induce mucosal antibody response with moderate doses of vaccine. The life of people for whom periodontal treatment cannot be easily obtained, get enhanced the quality of life.

**Materials and Methods:** PubMed (Medline), the National Institutes of Health, the Food and Drug Administration and the Center for Disease Control electronic databases were searched to extrapolate information on immune responses to immunization against periodontitis. A development of a multispecies vaccine targeting the four prime periodontal pathogens, viz *Porphyromonas gingivalis*, *Tannerella forsythia*, *Treponema denticola* and *Aggregatibacter actinomycetemcomitans*.

**Results:** Studies in non-human primate models using ligature-induced experimental periodontitis suggest that antibody responses by active immunization against *Porphyromonas gingivalis* can safely be induced, enhanced, and obtained over time.

Immune responses to whole bacterial cell and purified protein preparations considered as vaccine candidates have been evaluated in different animal models demonstrating that there are several valid vaccine candidates. Data suggest that immunization reduces the rate and severity of bone loss. It is also, temporarily, possible to alter the composition of the subgingival microflora. Natural active immunization by therapeutic interventions results in antibody titre enhancement and potentially improves treatment outcomes. Aloof vaccination of people utilizing *P. gingivalis* monoclonal antibodies briefly forestalls colonization of *P. gingivalis*. Probiotic therapy can be an unconventional approach. Administrative and security issues for human periodontal immunization preliminaries must be thought of.

**Conclusion:** Proof of principle that active and passive immunization can induce protective antibody responses is given. The impact of natural immunization and passive immunization in humans should be explored and may, presently, be more feasible than active immunization studies. We cannot ensure success in case of periodontal vaccine because of the complex etiopathogenesis of the disease.

**Keywords:** Vaccine; Immunity; Antibody; Antigen; *Porphyromonas gingivalis*

## Introduction

Vaccination is induction of immunity by injecting a dead or attenuated form of pathogen [1].

A world-first vaccine developed by Melbourne scientists, which reduced the need for surgery and antibiotics for severe gum disease. (I) Bacillus-Calmette-Guerin in vaccine against tuberculosis and cholera using live attenuated or killed bacteria, (II) polio and rabies vaccines using live attenuated viruses, (III) tetanus and diphtheria vaccines using bacterial cell antigen subunits, (IV) *Haemophilus influenza* and pneumococcus infections using conjugated vaccines and (V) synthetic vaccines, i.e. (HBV) against Hepatitis B.

Periodontitis is a typical medical issue, influencing about portion of individuals beyond 30 years old and over 70% of grown-ups beyond 65 years old. The 35% of population suffers from severe chronic periodontitis. Lamentably, albeit early location can forestall bone and tooth misfortune since this ailment advances without torment or noteworthy side effects, it is frequently far cutting edge before patients look for treatment. Around the world, the evaluated financial effect of periodontitis adds up to more than \$54 billion every year in lost profitability, and periodontitis is a significant supporter of the all out \$442 billion went through consistently on oral diseases [2].

The immunization targets chemicals delivered by the bacterium *Porphyromonas gingivalis*, to trigger a resistant reaction. This reaction produces antibodies that kill the pathogen's dangerous poisons. *P. gingivalis* is known as a cornerstone pathogen, which implies it can possibly twist the parity of microorganisms in dental plaque, causing infection.

### Challenge of utilizing antimicrobial medications for periodontitis have been:

1. The oral cavity has a mind boggling environment of microscopic organisms, a significant number of which are fundamental for wellbeing.
2. Plaque and periodontitis-causing microorganisms live inside a biofilm, in which they are physiologically unmistakable from planktonic cells of a similar life form. The utilitarian network of a biofilm is hard to upset without fundamental interruption.

Louis Pasteur coined the term 'vaccine'. These are preparations of live or killed microorganisms or their products used for immunization [3]. Three types of periodontal vaccine were employed for the control of periodontal diseases. These immunizations were set up from [4]:

- 1) Pure cultures of streptococci and different bacteria
- 2) Autogenous immunizations
- 3) Stock immunizations as van cott's, goldenberg's and so forth.

### Periodontitis as a polymicrobial infection

The current concept emerges from extensive research findings on the polymicrobial nature of the associated biofilm. This has prompted the idea that biofilm quality is the basic factor in the pathogenesis of periodontal illness. The microbes most habitually connected with periodontitis incorporate *Porphyromonas gingivalis*, *Prevotella intermedia*, *Tannerella forsythia* (*forsythensis*), *Treponema denticola*, *Actinobacillus actinomycetemcomitans* and *Fusobacterium spp.* Such bacteria and their by-products can elicit strong immune responses. Microscopic organisms in biofilm structures can be shielded from have immune reactions and are subject to ecological (passive response) and hereditary qualities (active response) factors [4].

The sorts of periodontal vaccination can be active or passive. Active vaccination incorporates entire bacterial cells, Sub-unit immunizations and Synthetic peptides as antigens while Passive inoculation incorporates murine monoclonal neutralizer and plantibodies.

### Active immunization

Active immunity is instigated by introduction to external antigen. This initiates lymphocytes to create antibodies against the antigen. The immune system of the host assumes a functioning job in reacting to the antigen. Entire-cell formalin-executed *P. gingivalis* has been used as the target antigen [5]. Active immunization confers specific immunity against infectious agents.

The degree of alveolar bone misfortune was straightforwardly associated to the degrees of PGE2. Reduced (PGE2) levels in GCF in inoculated creatures propose a constructive outcome of the vaccine, as PGE2 is a significant inflammatory facilitator and is related with bone loss [5].

### Passive immunization

Protective immunity can be obtained through passive immunization. This can be attained by move of explicit antibodies against the objective microscopic organisms (antigen). A passive immune reaction can be accomplished by transmission of antibodies by means of serum, lymphocytes from vaccinated people, or monoclonal antibodies against explicit pathogens. Transmission of maternal antibodies to the embryo is another case of passive vaccination. The upsides of utilizing counter acting agent particles to treat irresistible maladies incorporate their explicitness and adaptability. Passive immunization stays viable just as long as the infused counter acting agent continues, host won't react to the vaccination [5].

Antigens are infused into vector that produce antibodies. These antibodies when vaccinated into have achieve passive immunization. External layer proteins (OMPs) are significant coaggregation factors and as such are significant colonization elements of *P. gingivalis* [6]. Since IgG explicit for the 40 kDa-OMP hindered coaggregation of *P. gingivalis* vesicles and *S. gordonii*, it could possibly be utilized to forestall *P. gingivalis* infection [7].

### Pathogenesis of periodontitis

Pathogenic bacteria produce an array of antigens which stimulate proinflammatory cells and leads to production of wide variety of cytokines. These antigens can stimulate T-helper cells 1 or 2 (Th1 or Th2 respectively) cells. Antigens are taken up by dendritic cells and presented to CD4 or CD8 cells along with major histocompatibility complex (MHC) antigens [8]. Once bacteria break this barrier, cytokines are produced, which can be both pro inflammatory and anti-inflammatory. Creation of proinflammatory cytokines brings about periodontitis.

### Genetic immunization

By the mid 1990's, researchers had started to read new methodologies for the creation of antibodies that contrast in structure from customary ones. The technique includes genetic engineering or recombinant DNA innovation.

There are two types:

- Plasmid vaccines
- Live, viral vector vaccines

### Vaccine candidate antigens of *P. gingivalis*

*P. gingivalis* is a potential antibody competitor since this pathogen conveys a few high powerful antigens, a lipopolysaccharides, capsule, lipids and external layer proteins. Entire cell formalin-murdered *P. gingivalis* has been utilized as the objective antigen. Different

*P. gingivalis* antigens have been studied. The degree of alveolar bone destruction was straight connected to the levels of PGE2. Reduced (PGE2) levels in GCF in vaccinated creatures propose a constructive outcome of the immunization, as PGE2 is a significant inflammatory mediator and is related with bone loss [5]. Gingipains are categorized into two sorts of batches dependent on substrate explicitness [9]:

- 1) Gingipains R: It has 2 sorts RgpA and RgpB
- 2) Gingipain K (Kgp).

Most probiotic items contain microbes from the genera *Lactobacillus* or cell formalin-slaughtered *P. gingivalis* has been used as the target antigen [8]. Some microorganisms were considered as key pathogens in periodontal disease as they were strongly associated with disease status, disease progression and unsuccessful therapy. These were *P. gingivalis*, *T. forsythia* and *Aggregatibacter actinomycetemcomitans*. These were considered as key organisms as they satisfied the Socransky’s modification of Koch’s postulate [9]. Different *P. gingivalis* antigens have been studied and they are presented in table 1 and 2. A significant destructiveness factor of *P. gingivalis* is the extracellular noncovalently related complexes of Arg-X-and Lys-X-explicit cysteine proteinases and adhesins assigned the RgpA-Kgp complexes. In a study conducted by Torbjorn and Graham on Wistar rats, it was found that treatment with SRI172 (heat killed *Mycobacterium vaccae*) inhibited progression of established experimental periodontal disease. The SRI172, a preparation of high temperature destroyed *M. vaccae* had shown to down regulate Th2 responses and increase Th1 responses to bacteria, and hence have therapeutic effect in periodontal disease [10]. Stimulation of self-antibody production as a consequence of treatment of infected tissues causing bacteraemia can induce an elevation of antibodies against a target antigen. Several studies have assessed the effects of such “uncontrolled” immunization against pathogens associated with periodontitis (Table 3).

Study	Antigen	Study type	Results	Conclusion
Moritz., et al. (1998)	Purified cysteine protease (porphypain-2) from <i>P. gingivalis</i> versus placebo immunization. For experimental protocol, see Ebersole., et al. (1991)	Case-control study of experimental periodontitis in <i>M. fascicularis</i>  Clinical measures, and radiographic analysis (CADIA)  ELISA assays	1. Elevated serum IgG titres to whole cell <i>P. gingivalis</i> (36-fold) and Porphypain-2 (194-fold)  2. 25% more Gram-negative bacteria at control sites than in immunized animals  3. Few clinical changes as an effect of immunization  4. No statistically significant changes as defined by CADIA between sham- or test-immunized animals	Immunization with porphypain-2 induces an immune response immunization may impact microbial colonization clinical effect remains unclear
Persson., et al. (1994)	Vaccine composed of formalin-killed whole-cell <i>P. gingivalis</i> (5083, primate strain) and Syntex SAF) adjuvant	Case-control study of 10110 active/ shamimmunized <i>M. fascicularis</i> with  pre-existing low IgG titres but presence  of <i>P. gingivalis</i> in pockets over 44 weeks with infectious challenge at week 36. Immunization at baseline  weeks 3, 6, and 16 when ligatures were placed. Routine clinical measures,  standardized radiographs (CADIA),  ELISA assays, and DNA probe analysis	1. Serum IgG titre to <i>P. gingivalis</i> elevation through immunization with 50% titre levels remaining at endpoint  2. Trend towards less <i>P. gingivalis</i> in immunized animals.  3. Significantly more bone loss in control animals at ligated sites and exaggerated by microbial challenge  4. Variety in antibody response	Immunization with formalin-killed whole-cell <i>P. gingivalis</i> with an adjuvant inhibits progression of experimental periodontitis

Persson, et al. (1994)	DNA probe analysis of the microflora in relation to clinical features	Cross-section study of the oral microflora in <i>M. fascicularis</i> Routine clinical periodontal measures	1. <i>A. actinomycetemcomitans</i> , <i>P. gingivalis</i> , <i>P. intermedia</i> , <i>C. rectus</i> , <i>T. forsythia</i> , <i>F. nucleatum</i> present in majority of sites tested in non-experimental conditions  2. Antibody titre levels to <i>P. gingivalis</i> inversely correlated with <i>P. gingivalis</i> levels	<i>M. fascicularis</i> appears to be a suitable model in which studies of vaccine efficacy for control of periodontitis can be tested
Ebersole, et al. (1990)	<i>A. actinomycetemcomitans</i> leucotoxin produced in a vector DNA model was used to immunize <i>M. fascicularis</i>	Development and testing of a leucotoxin vaccine derived from <i>A. actinomycetemcomitans</i> and tested in <i>M. fascicularis</i> to assess serum responses. Case-control animal study	1. Most <i>M. fascicularis</i> carried antibody titres to <i>A. actinomycetemcomitans</i>  2. Primary immunization elicited Ig1 and Ig3 responses  3. Secondary response elicited IgG2 responses and increased antibody avidity	A host response to immunization with <i>A. actinomycetemcomitans</i> leucotoxin with potential efficacy possible
Niesengard, et al. (1989)	<i>B. macacae</i> (non-human primate equivalent to <i>P. gingivalis</i> in humans)	Preliminary case-control study in <i>M. fascicularis</i>  Ligature-induced periodontitis  12-week immunization period  Clinical measures, GCF radiographs  Serum titres to <i>B. macacae</i>	1. Immunization-induced elevated antibody IgG titres to <i>B. macacae</i>  2. Ligatures-induced bone loss in all animals  3. Levels <i>B. macacae</i> were 2 times higher in non-immunized animals after 6 months	Heightened immune responses and partial prevention of microbial colonization
Zhang, et al. 2009	Female BALB/c mice 40-kDa OMP of <i>P. gingivalis</i> (40k-OMP) sublingually with a cDNA vector pFL	Non-randomized controlled study	Serum IgG and IgA and salivary IgA Ab responses. Alveolar bone loss	Significant serum IgG and IgA and salivary IgA Ab responses that were comparable to those induced by 40k-OMP plus cholera toxin as adjuvant. Sublingual immunization with 40k-OMP plus pFL induced both IgG1 and IgG2a Ab responses. Sublingual 40k-OMP plus pFL administration showed a significant reduction of alveolar bone loss caused by oral infection with <i>P. gingivalis</i>

**Table 1:** Examples of non-human primate study models and results from vaccine trials against periodontitis.

Study	Antigen	Study type	Results	Conclusion
Gemzell, <i>et al.</i> (2004)	<i>F. nucleatum</i> ATCC 25586, <i>P. gingivalis</i> ATCC 33277, Viable bacteria used in immunization schedule	27 BALB/c female mice. Various immunization schedules and a placebo group (intra-peritoneal injections once per week (4 weeks)	1. ELISA and chemiluminescence assays 2. Production of both IgG1 and IgG2 subclass antibodies and higher levels for the combination vaccine <i>P. gingivalis</i> / <i>F. nucleatum</i>	A vaccine candidate may be enhanced by combinations of <i>P. gingivalis</i> and <i>F. nucleatum</i>
Ross, <i>et al.</i> (2004)	<i>P. gingivalis</i> YH522, ATCC 33277, ATCC53978 12 clinical isolates from Seattle, Norway, Romania, Sudan	Genetics research and animal vaccine study with constructed gene vaccine using knockout mice challenged to <i>P. gingivalis</i> infection	1. The gene and expressions of PGO695 and PGO0694 are soluble and potentially useful as vaccine candidates	Additional work needed to improve results to enhance solubility. There is a loss in epitope domains when using truncated versions of proteins as vaccines.
DeCarlo, <i>et al.</i> (2003)	<i>P. gingivalis</i> ATCC 33277, HA2 sequence (Genbank PGU68468.1) cloned with <i>E. coli</i>	Fischer CD F(344) rats Test group recombinant HA2 (8 animals) Placebo group (Freunds' adjuvant) (8 animals) 3 immunizations	1. Sham-immunized animals developed no anti-rHA2 IgG2 antibodies, whereas rHA2-immunized animals did develop IgG antibodies measurable over 70 days	Protective effect against bone loss in the absence of adjuvant in the vaccine.
Rajapakse, <i>et al.</i> (2002)	Whole-cell killed <i>P. gingivalis</i> ATCC 33277/ ATCC539781 adjuvant Rgp (ArgX and LysX proteinase) 1 adjuvant	4 groups (2 of them (sham immunized)) of Sprague-Dawley rats 2 immunizations with 3-week intervals. After antibiotics treatment challenged with <i>P. gingivalis</i> infection	1. Immunization with the RgpA-Kgp <i>P. gingivalis</i> W50-induced high IgG titres 2. Immunization restricted colonization with <i>P. gingivalis</i> ATCC 33277	Immunization with Kgp39 and Rgp44 may prevent or reduce periodontitis in humans.
Gibson III, <i>et al.</i> (2001)	<i>P. gingivalis</i> A7A1-A28	BALB/c mice Gingipain PgpA and RgpB whole-cell heat-killed <i>P. gingivalis</i> 3 immunizations	1. Immunizations with gingipains PrgA and PrgB stimulate <i>P. gingivalis</i> serum IgG antibodies 2. Purified denaturated PgpA and RgpB identified 5 polypeptide bands identified as 45, 44, 17, 15, 27 kDa 3. Immunization with RgpA but not RgpB protects against <i>P. gingivalis</i> -induced bone loss.	Whole-cell heat-killed <i>P. gingivalis</i> and gingipain RgpA (haemagglutinin domain) provide protection against bone loss
O'Brien-Simpson, <i>et al.</i> (2000)	<i>P. gingivalis</i> ATCC 33277, <i>P. gingivalis</i> W50	BALB/c mice immunized with Rgp-Kgp proteinase adhesion complex of ATCC 33277 or W50 with or without adjuvant (IFA) abdominal injections	1. When challenged with W50 postimmunization, those immunized against W50 showed significantly smaller abdominal lesions 2. When challenged with ATCC 33277, no lesions were found postimmunization 3. Protection against <i>P. gingivalis</i> infection may be mediated via Fc receptor-dependent phagocytosis	RgpA-Kgp protein-adhesin complex protects against <i>P. gingivalis</i> challenge in the murine model

<p>Katz., et al. (1999)</p>	<p><i>P. gingivalis</i> ATCC 33277, 381, A7A1-A28</p> <p>Hagb gene from 381 was cloned in a pET vector and expressed in <i>E. coli</i></p>	<p>Fischer CD F 344 rats were immunized with recombinant Hagb plus Freund's adjuvant subcutaneously and then orally exposed to fresh <i>P. gingivalis</i> at days 13 and 14 post-immunization</p>	<ol style="list-style-type: none"> <li>1. No elevation in salivary IgA as a result of immunization</li> <li>2. Serum IgG elevated in immunized infected and in infected-only animals</li> <li>3. Supernatants from rHagb immunized stimulated lymphoid cell cultures with high levels of interferon, followed by IL2, IL-1 and then IL-4 consistent with Thelper type 1 (Th1) and Th2 responses rHagb reacted with <i>P. gingivalis</i> ATCC 33277, 381, A7A1-A28, and W50 with a 50 kDa protein band representing rHagb</li> </ol>	<p>Immunization with purified rHag B induces protective immunity against <i>P. gingivalis</i> infection and provides a potential vaccine candidate against chronic periodontitis in humans</p>
<p>Genco., et al. (1998)</p>	<p><i>P. gingivalis</i> A7436 and HG66-extracted cysteine protease (GingipainR)</p>	<p>148 BALB/c female mice: non-immunized, Peptide A, Peptide D, Whole-cell, Gingipain R1 (95 kDa), Gingipain R2 (50 kDa)</p>	<ol style="list-style-type: none"> <li>1. When challenged with <i>P. gingivalis</i>, non-immunized and peptide A immunized develop ulcerated lesions, weight loss</li> <li>2. Gingipain R immunized were protected from abscess formation</li> <li>3. Reduction in viable <i>P. gingivalis</i> counts</li> <li>4. Antisera from <i>P. gingivalis</i> HG66 recognize gingipains from many different <i>P. gingivalis</i> strains</li> </ol>	<p>Immunization with gingipain R provides protection against <i>P. gingivalis</i> infection in mice</p>
<p>Evans., et al. (1992)</p>	<p><i>P. gingivalis</i> 381, 2561 and <i>P. gingivalis</i> ATCC 33277 fimbriae</p>	<p>Germ-free Sprague-Dawley rats (6 groups of 8 rats per group), Sham-immunized non-infected, Sham-immunized infected, Whole-cell heat-killed <i>P. gingivalis</i>, Purified 43 kDa protein, Purified 75 kDa protein, Combined 43 and 75 kDa vaccine</p>	<ol style="list-style-type: none"> <li>1. 43 kDa immunized were protected from alveolar bone loss</li> <li>2. 75 kDa immunized had no protection against bone loss</li> <li>3. The combination 43, and 75 kDa provided protection</li> <li>4. Gingival fluid collagenase activity reduced in 43 kDa immunized animals</li> </ol>	<p>43 kDa fimbrial protein may be useful as a vaccine candidate against periodontitis</p>

Table 2: Examples of murine study models and results from vaccine trials.

Study	Antigen	Study type	Results	Conclusion
Aukhil., et al. (1988)	<i>P. gingivalis</i> , <i>A. viscosus</i> , <i>P. intermedia</i> , <i>T. vincentii</i> , <i>T. denticola</i>	Longitudinal case series of 23 subjects with CP over 12 months serum IgG ELISA assay	Reduction in serum IgG titres to: <i>P. gingivalis</i> , <i>A. viscosus</i> , <i>F. nucleatum</i> , <i>P. intermedia</i> , <i>T. vincentii</i> , <i>T. denticola</i> . Unclear for Capnocytophaga spp.	No immunity effect resulting in sustained titres at one year
Kohyama (1989) (only abstract review, publ. in Japanese)	<i>P. gingivalis</i> , <i>A. viscosus</i> , <i>A. actinomycetemcomitans</i> (serotype a), <i>P. intermedia</i>	Longitudinal case series of subjects with CP (n552) before and after ICRT serum IgG ELISA assay	1. Subjects with CP had higher serum IgG titres to <i>P. gingivalis</i> , <i>P. intermedia</i> , <i>A. actinomycetemcomitans</i> than healthy controls 2. Titres increased after therapy, whereas the presence of pathogens decreased	Subjects with CP experience elevated serum IgG titres to pathogens associated with periodontitis. Potential passive immune response
Chen., et al. (1995)	<i>P. gingivalis</i> (ATCC 33277)	Longitudinal case-control study. 36 subjects with AP and 20 healthy controls. Whole-cell-purified LPS, and protein fractions from <i>P. gingivalis</i> . Serum IgG ELISA titre chemiluminescence assays	1. IgG titres to LPS and protein fractions in subjects with high baseline titres decreased after ICRT, but increased in those with low baseline titre 2. Avidities increased for all subjects after treatment	Subjects with untreated AgP may not produce functional antibodies against <i>P. gingivalis</i> infection. Treatment results in elevation of titres against <i>P. gingivalis</i>
Johnson., et al. (1993)	<i>P. gingivalis</i> (ATCC 33277)	Longitudinal case series 28 subjects with AP (12-month study) serum IgG ELISA titre assay to <i>P. gingivalis</i>	1. Serum IgG titre decrease from 3 <sup>rd</sup> to 12 <sup>th</sup> months after ICRT after concurrent with clinical improvement	Elevated serum titres were not observed as effect of treatment. Serum IgG titres' decrease consistent with clinical improvements
Sjo"stro"m., et al. (1994)	<i>A. actinomycetemcomitans</i> (ATCC 43718 serotype b, strain Y4)	Case intervention longitudinal study (12 months). Subjects (22 with AgP, 20 healthy controls) serum IgG ELISA antibody titre assay to <i>A. actinomycetemcomitans</i> Chemiluminescence (CL) assay (PMN cell-killing capacity)	1. Sero-conversion one year after ICRT 2. Elevated IgG serum antibodies in sero-negative subjects to whole-cell and LPS from <i>A. actinomycetemcomitans</i> antigen 3. Increased CL capacity	ICRT results in a humoral immune response in sero-negative subjects consistent with beneficial treatment effects
Mooney., et al. (1995)	<i>P. gingivalis</i> (NCTC 11834), <i>A. actinomycetemcomitans</i> (ATCC 29523)	Longitudinal case-control intervention study of 18 subjects with CP and 23 healthy controls. Samples prior to and 3 months after completion of ICRT Serum IgG ELISA assay, avidity assay (ammonium thiocyanate)	1. Enhanced avidity and serum IgG titres to <i>P. gingivalis</i> and <i>A. actinomycetemcomitans</i> in sero-positive CP cases 2. Elevated serum IgG ELISA titres in sero-negative CP subjects 3. No differences in treatment effect explained	Unique humoral immune responses previous exposure to pathogens of significance



Horibe., et al. (1995)	<i>P. gingivalis</i> (ATCC FDC 381), <i>P. intermedia</i> (ATCC 25611), <i>P. Loescheii</i> (ATCC 15930), <i>F. nucleatum</i> (ATCC 25586), <i>A. actinomycetemcomitans</i> (ATCC Y 4), <i>E. corrodens</i> (FDC 1073), <i>C. ochraea</i> (M1)	Longitudinal case series with 20 AP subjects. Serum IgG ELISA assay	<ol style="list-style-type: none"> <li>1. Decrease in serum IgG titres to <i>P. gingivalis</i>, <i>P. intermedia</i></li> <li>2. Decrease in serum IgG titres consistent with suppression of pathogens in subgingival plaque</li> </ol>	Study failed to demonstrate passive immunization effect study suggested that serum titres linked to presence of bacteria in plaque
Smith., et al. (1996)	<i>A. actinomycetemcomitans</i> (ATCC 45718 serotype b, strain Y4, <i>P. gingivalis</i> (ATCC 33277), <i>T. forsythensis</i> (clinical)	Case intervention study over 2 months in 18 subjects with IDDM type 1 and CP. Serum IgG ELISA antibody titre assay	<ol style="list-style-type: none"> <li>1. Treatment did not eliminate the bacteria studied</li> <li>2. Limited treatment effects</li> <li>3. No effect on serum IgG titres</li> </ol>	No evidence of passive immunization in subjects with IDDM
Booth., et al. (1996)	Radioimmunoassay for serum IgG, Iga, IgM	Longitudinal case-control study of subjects with periodontitis. Monoclonal antibody to <i>P. gingivalis</i> (MAb 61GB 1.3) or placebo in subgingival applications	1. No impact on difference in decrease of periodontal measures other than for <i>P. gingivalis</i>	Passive immunization can selectively prevent colonization of <i>P. gingivalis</i> for up to 9 months
Papapanou et al. (2004)	Antigens from 19 different bacteria including: <i>P. gingivalis</i> (FDC 381) <i>P. intermedia</i> (ATCC 25611) <i>P. nigrescens</i> (ATCC 33563) <i>T. forsythensis</i> (ATCC 43037)	Longitudinal intervention case-control study 89 CP patients and healthy control subjects. Checkerboard immunoblotting	<ol style="list-style-type: none"> <li>1. No impact on serum IgG titres as an effect of therapy</li> <li>2. Higher titres in CP subjects</li> <li>3. Different patterns of titres between CP and healthy subjects</li> </ol>	Titres linked to the presence and challenge from microbiota no effect on titters suggesting passive immunization

**Table 3:** Summary of findings from human studies on serum titre responses to therapy or passive immunization in subjects with aggressive periodontitis (AgP) or chronic periodontitis (CP).  
ICRT: Initial Cause Related Therapy.

**Future of periodontal vaccines**

Periodontal vaccine trials aim to stimulate the immune system to produce increased levels of immunoglobulin of desired specificity immunization of dendritic cells pulsed with antigens, the use of improved adjuvant formulas (e.g. the use of alum as an alternative to HSP-based adjuvant), the use of recombinant plant monoclonal antibodies (plantibodies) and the use of transgenic microorganisms as antigen vectors [11].

**DNA vaccines offer several distinct advantages like**

- a) Can be manufactured more easily.
- b) DNA is stable by nature.
- c) Simplicity of changing the sequences encoding antigenic proteins.
- d) The immunogenicity of the modified protein may be directly assessed following an injection of DNA vaccine.

*P. gingivalis*-explicit partner T cell clones got from mice vaccinated with *P. gingivalis* alone had a Th1 profile while those got from mice inoculated with *F. nucleatum* preceding *P. gingivalis* had a Th2 profile. The last research bunch additionally revealed that enemy of *F. nucleatum* counter acting agent inspired by inoculation of *F. nucleatum* before *P. gingivalis* down adjusted the opsonophagocytic capacity of against *P. gingivalis* insusceptible serum infusion of DNA vaccine [12].

An immunization consolidating the poly-receptive monoclonal immunizer perceived peptide number 19 of 37 manufactured peptides spreading over the entire atom of *P. gingivalis* HSP60 may be valuable in multi factorial infections, for example, atherosclerosis and diabetes supporting the job of atomic mimicry in the periodontal-atherosclerosis link [13].

**Periodontal injections against *A. actinomycetemcomitans***

*A. actinomycetemcomitans* is a significant pathogen in human periodontal illness, in aggressive periodontitis. An engineered oligopeptide was organised, dependent on the amino acid arrangement of *A. actinomycetemcomitans* fimbriae which was seen as compelling in rabbit model, guaranteeing restraint of grip and its ensuing colonization [14].

**Limitations**

- a) Multi factorial and complex nature of periodontal disease.
- b) Maintaining satisfactory immune response levels for longer periods.
- c) Contamination of vaccine.
- d) To arouse helper T-cell polarization that uses cytokine purposes optimum for protection against bacteria and tissue destruction.
- e) Toxic reactions to inactivated whole vaccines [15].

Lee., *et al.* [16] conducted a study to evaluate the performance of *P. gingivalis* HSP60 as an immunization up-and-comer. Rodents were inoculated with *P. gingivalis* HSP60 and test alveolar bone misfortune was instigated by the disease with numerous periodontopathogenic microbes. Results indicated an exceptionally solid converse connection between post-immune anti-*P. gingivalis* HSP immunoglobulin G (IgG) levels and the measure of alveolar bone misfortune instigated by either *P. gingivalis* or numerous bacterial disease.

Yonezawa., *et al.* [17] in their examination assessed the defensive capability of rgpA DNA antibody against a deadly test of *P. gingivalis* and furthermore broke down the enlistment of cell safe reactions by the DNA immunization. In light of the outcomes, it gave the idea that inoculation with the rgpA DNA antibody may actuate both humoral and cell safe reactions for security against *P. gingivalis* challenge, further showed that constricted unreasonable interferon- $\gamma$  creation in creatures vaccinated with a rgpA DNA antibody may assume a key job in insurance against *P. gingivalis* disease. O'Brien-Simpson., *et al.* [18] led an investigation to show that *P. gingivalis* W50 entire cells show a similar restricting example to fibrinogen, fibronectin, hemoglobin and collagen Type V as the arginine- and lysine-specific cysteine

protease complex (RgpA-Kgp complex), which ties to these proteins with nanomolar separation constants. They likewise demonstrated that the adhesins of the RgpA-Kgp complex are significant in giving security in the murine injury and periodontitis models when the complex is utilized as an immunization and that the safe reaction is predominately a Th2 reaction. The outcomes proposed that when the RgpA-Kgp intricate or utilitarian restricting theme, or dynamic site peptides are utilized as an immunization, they initiate a Th2 reaction that squares capacity of the RgpA-Kgp complex and secures against periodontal bone misfortune. Evans., *et al.* [19] there are contrasting suppositions on whether mucosal or fundamental counter acting agent reactions are significant for security against periodontal sickness. Generally, inoculation with suitable antigens driving overwhelmingly toward either sort of humoral reaction has brought about huge security. Herminajeng., *et al.* discovered that mice inoculated with antisurface-associated material from *A. actinomycetemcomitans* displayed an ascent in defensive counter acting agent levels going about as an opsonin [20].

## Conclusion

To forestall colonization of periopathogens, inoculation might be a significant adjunctive treatment to mechanical debridement in people, however broad research toward this path may hold a promising future being developed of periodontal antibodies. A modern immunization structure routine focusing on different pathogenic species is certainly required against periodontitis and periodontitis initiated fundamental maladies. (I) There is adequate agreeing proof that serum antibodies against *P. gingivalis* antigens are prompted by either disease or inoculation. (II) There are non-human primate and murine investigation results with proof of explicit strategies to actuate a suffering immune response titre without unmistakable fundamental reactions. The vagueness in some investigation results may rely more upon the examination model (ligature-instigated ailment) than immunization viability. High counter acting agent titres seem to give security. (III) Immunization against *P. gingivalis* brings about a decrease of the amount of the objective life form in creature models. *P. gingivalis* levels at contaminated periodontal locales are contrarily related with immune response titres against the pathogen. (IV) Collaborative endeavors are expected to guarantee effective immunization improvement against periodontitis.

## Bibliography

1. Roderich N. "Immunology". In: Brooks GF, Butel JS, Morse SA, editors. Javetz, Meink and Adelberg's Medical Microbiology. 23<sup>rd</sup> edition 121 (2004).
2. Listl S., *et al.* "Global economic impact of dental diseases". *Journal of Dental Research* 94 (2015): 1355-1361.
3. Reid R and Roberts F. "Textbook of pathology illustrated". 6<sup>th</sup> edition. Churchill Livingstone (2005): 677.
4. Socransky SS and Haffajee AD. "Microbiology of periodontal disease". In: Lindhe J, Karring T, Lang NP, editors. Clinical Periodontology and Implant Dentistry, 4<sup>th</sup> edition. Oxford: Blackwell Munksgaard (2003).
5. Persson RG. "Immune responses and vaccination against periodontal infections". *Journal of Clinical Periodontology* 32.6 (2005): 39-53.
6. Mouton C., *et al.* "Immunochemical identification and preliminary characterization of a nonfimbrial hemagglutinating adhesin of *Bacteroides gingivalis*". *Infection and Immunity* 57 (1989): 566-573.
7. Maeba S., *et al.* "Transcutaneous Immunization With a 40-kDa Outer Membrane Protein of *Porphyromonas gingivalis* Induces Specific Antibodies Which Inhibit Coaggregation by *P. gingivalis*". *Vaccine* 23.19 (2005): 2513-2521.
8. Kesavalu L., *et al.* "*Porphyromonas gingivalis* virulence in mice: induction of immunity to bacterial components". *Infection and Immunity* 60.4 (1992): 1455-1464.
9. Cholan PK., *et al.* "Periodontal vaccine: A short synopsis". *SRM Journal of Research in Dental Sciences* 3 (2012): 240-246.

10. Malhotra R., et al. "Periodontal vaccine". *Indian Journal of Dental Research* 22.5 (2011): 698-705.
11. Shin EA., et al. "Langridge WHO Synthesis and assembly of an adjuvanted *Porphyromonas gingivalis* fimbrial antigen fusion protein in plants". *Protein Expression and Purification* 47 (2006): 99-109.
12. Choi JI., et al. "Fusobacterium nucleatum impairs serum binding to *Porphyromonas gingivalis* biofilm". *Oral Microbiology and Immunology* 18 (2003): 92-94.
13. Choi JI., et al. "Immunoreactivity of poly-specific peptide from *Porphyromonas gingivalis* heat shock protein (Abstract 2716). 88th General Session and Exhibition of the IADR Barcelona, Spain?". Barcelona: International Association for Dental Research (2010).
14. Harano K., et al. "An antiserum to a synthetic fimbrial peptide of *Actinobacillus actinomycetemcomitans* blocked adhesion of the microorganism". *FEMS Microbiology Letters* 130 (1995): 279-285.
15. Kudyar N., et al. "Periodontal Vaccine: A dream or reality". *Journal of Indian Society of Periodontology* 15 (2011): 115-120.
16. Lee JY., et al. "*Porphyromonas gingivalis* heat shock protein vaccine reduces the alveolar bone loss induced by multiple periodontopathogenic bacteria". *Journal of Periodontal Research* 41 (2006): 10-14.
17. Yonezawa H., et al. "Immunization by Arg-gingipain A DNA vaccine protects mice against an invasive *Porphyromonas gingivalis* infection through regulation of interferon-gamma production". *Oral Microbiology and Immunology* 20 (2005): 259-266.
18. O'Brien-Simpson NM., et al. "An immune response directed to proteinase and adhesin functional epitopes protects against *Porphyromonas gingivalis*-induced periodontal bone loss". *Journal of Immunology* 175 (2005): 3980-3989.
19. Evans RT., et al. "Immunization with *Porphyromonas* (Bacteroides) *gingivalis* fimbriae protects against periodontal destruction". *Infection and Immunity* 60 (1992): 2926-2935.
20. Herminajeng E., et al. "Protective humoral immunity induced by surface-associated material from *Actinobacillus actinomycetemcomitans* in mice". *Microbes and Infection* 3 (2001): 997-1003.
21. Moritz AJ., et al. "Immunization with *Porphyromonas gingivalis* cysteine protease effects on experimental gingivitis and ligature induced periodontitis in *Macaca fascicularis*". *Journal of Periodontology* 69 (1998): 686-697.
22. Persson GR., et al. "Immunization against *Porphyromonas gingivalis* inhibits progression of experimental periodontitis in nonhuman primates". *Infection and Immunity* 62 (1994a): 1026-1031.
23. Persson GR., et al. "*Macaca fascicularis* as a model in which to assess the safety and efficacy of a vaccine for periodontitis". *Oral Microbiology and Immunology* 9 (1994b): 104-111.
24. Ebersole JL., et al. "Molecular approaches to leukotoxin as a virulence component to *Actinobacillus actinomycetemcomitans*". *Archives Oral Biology* 35 (1990): 69S-78S.
25. Niesengard R., et al. "Effects of immunization with *B. macace* on induced periodontitis. Preliminary findings". *Immunological Investigations* 18 (1989): 225-237.
26. Zhang T., et al. "Sublingual vaccination with outer membrane protein of *Porphyromonas gingivalis* and Flt3 ligand elicits protective immunity in the oral cavity". *Biochemical and Biophysical Research Communications* 390 (2009): 937-941.
27. Gemmell E., et al. "Modulation of the antibody response by *Porphyromonas gingivalis* and *Fusobacterium nucleatum* in a mouse model". *Oral Microbiology and Immunology* 19 (2004): 247-251.
28. Ross CR., et al. "Characterization of two outer membrane protein antigens of *Porphyromonas gingivalis* that are protective in a murine lesion model". *Oral Microbiology and Immunology* 19 (2001b): 6-15.

29. DeCarlo AA, et al. "Feasibility of an HA2 domain-based periodontitis vaccine". *Infection and Immunity* 71 (2003): 562-566.
30. Rajapakse PS, et al. "Immunization with the RgpA-Kgp proteinase-adhesin complexes of *Porphyromonas gingivalis* protects against periodontal bone loss in the rat periodontitis model". *Infection and Immunity* 70 (2002): 2480-2486.
31. Gibson FC III. and Genco RA. "Prevention of *Porphyromonas gingivalis* induced oral bone loss following immunization with GingipainR1". *Infection and Immunity* 69 (2001): 7959-7963.
32. O'Brien-Simpson NM, et al. "RgpA-Kgp peptide based immunogens provide protection against *Porphyromonas gingivalis* challenge in a murine lesion model". *Infection and Immunity* 68 (2000): 4055-4063.
33. Katz J, et al. "Host responses to recombinant hemagglutinin B of *Porphyromonas gingivalis* in an experimental rat model". *Infection and Immunity* 67 (1999): 4352-4359.
34. Genco CA, et al. "A peptide domain on gingipain R which confers immunity against *Porphyromonas gingivalis* infection in mice". *Infection and Immunity* 66 (1998): 4108-4114.
35. Aukhil I, et al. "The effects of periodontal therapy on serum antibody (IgG) in plaque microorganisms". *Journal of Clinical Periodontology* 15 (1988): 544-550.
36. Kohyama A. "Microbiological and serological investigation of periodontal disease activity". *Nippon Shishubyo Gakkai Kaishi* 31 (1989): 360-379.
37. Chen HA, et al. "Immunodominant antigens of *Porphyromonas gingivalis* in patients with rapidly progressive periodontitis". *Oral Microbiology and Immunology* 10 (1995): 193-201.
38. Johnson V, et al. "Effects of treatment on antibody titer to *Porphyromonas gingivalis* in gingival crevicular fluid of patients with rapidly progressive periodontitis". *Journal of Periodontology* 64 (1993): 559-565.
39. Sjöström K, et al. "Effect of treatment on titer, function, and antigen recognition of serum antibodies to *Actinobacillus actinomycetemcomitans* in patients with rapidly progressive periodontitis". *Infection and Immunity* 62 (1994): 145-151.
40. Mooney J, et al. "Initial serum antibody titer to *Porphyromonas gingivalis* influences development of antibody avidity and success of therapy for chronic periodontitis". *Infection and Immunity* 63 (1995): 3411-3416.
41. Horibe M, et al. "Effect of periodontal treatments on serum IgG antibody titer to periodontal bacteria". *Journal of Clinical Periodontology* 22 (1995): 510-515.
42. Smith GT, et al. "Short-term responses to periodontal therapy in insulin-dependent diabetic patients". *Journal of Periodontology* 67 (1996): 794-802.
43. Booth V, et al. "Passive immunization with monoclonal antibodies against *Porphyromonas gingivalis* in patients with periodontitis". *Infection and Immunity* 64 (1996): 422-427.
44. Papapanou P, et al. "Longitudinal stability of serum immunoglobulin G responses to periodontal bacteria". *Journal of Clinical Periodontology* 31 (2004): 989-990.

**Volume 19 Issue 6 June 2020**

**©All rights reserved by Rimi Najeeb, et al.**